Elite Pharmaceuticals Inc(OTCBB:ELTP) Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufactures of oral, controlled-release products, using technology. Elite owns, licenses or contract manufactures eight products which are being sold commercially. These products are Phentermine 37.5 milligram tablets, Methadone 10 milligram tablets, Lodrane D Immediate Release capsules, Hydromorphone Hydrochloride 8 milligram tablets, Phendimetrazine tartrate 35 milligram tablets, Phentermine 15 milligram capsules, Phentermine 30 milligram capsules and Naltrexone HCl 50milligram tablets. The Company focuses on the development of various types of drug products, including branded drug products which require new drug applications. The Company offers both, branded and generic products in various therapeutic categories.

Analytical Analysis

Elite Pharmaceuticals Inc(OTCBB:ELTP) has been moving in a series of crest and through since start of the year ,2015, but the stock did saw a major bullish rally in the month of February , 2014 when it touched its high of $0.33 at a trading volume of around $6 million.

After February ELTP facing a downward trend till now.

The share price saw it’s highest of $0.51 while its lowest was $0.17 in 52-weeks time. The stock maintains good liquidity with average volume of 0.24 million shares per day.

Promotional Analysis

Elite Pharmaceuticals Inc(OTCBB:ELTP) is out of news for a long ti,e and we didn’t hear anything from Elite since February 2015. Last time at 17^th of February Elite Pharmaceuticals Inc released a PR statement in which they reported the financial results for the third quarter of Fiscal Year 2015.Snce then there is no news from Elite Pharmaceuticals and in my opinion this unprofessional behaviour could lead to customer liquidation.

Conclusion

Elite Pharmaceuticals Inc(OTCBB:ELTP) is a typical development stage company with $8.27 million cash and total assets of $25.70 million. The company has total liabilities of $56.24 million resulting in negative equity despite of injection of Additional Capital of $ 156.17 during the year. ELTP trading in green and continues to trade in impressive volume, however does not seem to be moving anywhere close to its earlier position in the near future.

 Considering the fundamentals its market capitalization of $158.00 million is clearly overstated.

http://www.elitepharma.com/